The American College of Cardiology recommends continuing baseline statin therapy, as GLP-1 receptor agonists provide complementary cardiovascular benefits rather than serving as statin substitutes
Image Credit: DukiPH / Shutterstock.com Introduction Orforglipron is an orally bioavailable next-generation glucagon-like peptide 1 (GLP-1) receptor agonist (GLP-1RA) that has emerged as a potential alternative to injectable agents like semaglutide based on early Phase 1, 2, and 3 clinical trials demonstrating glucose-lowering and weight-loss efficacy without the need for injection-based delivery
*Based on a 2024 survey of pharmacists who recommend branded vitamins and supplements
Lilly's massive R&D budget has also allowed it to focus on retatrutide, a so-called "triple-agonist" combining GLP-1 properties with other medications, that is currently in trial
Resistance training or strength-based movement
Concerns over more severe adverse effects, including pancreatitis and possible thyroid tumors, may further deter both patients and healthcare providers from utilizing these medications
